Bind and AstraZeneca, Pfizer, Amgen

Company: Bind Therapeutics ($BIND)
Partners: AstraZeneca ($AZN), Pfizer ($PFE), Amgen ($AMGN)
Technology: Cancer-targeted nanoparticles
Amount: AstraZeneca, $69 million up front and up to $130 million in milestones; Pfizer, $50 million up front and up to $160 million in milestones; Amgen, $46.5 million up front and up to $134 million in milestones

The scoop: MIT professor and entrepreneur Robert Langer's Bind Therapeutics had a prolific year on the partnerships front. On top of a $70.5 million IPO in September, the Cambridge, MA, company raked in the partnerships in 2013, linking up with three behemoth drug developers to help them deliver cancer drugs with Bind's Accurin targeting nanotechnology.

With its cancer drug delivery platform in tow, Bind tied up with Amgen in the first few days of 2013 for a total of more than $175 million, $46.5 of that in upfront and development milestones and the rest in regulatory and sales marks down the road. Then in April, the company picked up two more high-profile deals: a $50 million contract with Pfizer with up to $160 million more in milestones, and a partnership with AstraZeneca for almost $200 million, including $69 million up front.

Accurin technology for cancer drug delivery--Courtesy of Bind

It's safe to say Bind's tech was a hot commodity this past year, and if the sheer dollar amount is any indication, it's seen as a worthwhile investment even this early in its clinical program. Bind's Accurins are designed to deliver cancer drugs to solid tumors in high concentrations. The programmed vehicles have antibodies on their surface and are designed to hold cancer drugs within, taking the drugs where they need to be while protecting healthy surrounding cells from the toxic treatments.

Bind also has its own mid-stage drug in trials, BIND-014, which uses its delivery platform to carry docetaxel to tumors.

"Drug delivery and nanotechnology in particular are going to be even more important as time goes on and as new molecules are invented," Langer told FierceDrugDelivery in November. "With more and more clinical trials surfacing, I think [nanotechnology] will continue to be very important for new molecules. It's pretty unlimited actually, in terms of the way people are using it."

For more:
Special report: 2008 Fierce 15 - BIND
Bob Langer biotech lands first big biopharma deal with Amgen
Resurgent Pfizer partners with Bind on new nanotech drug effort
AstraZeneca and Boston biotech unite to blast cancer with a nanotech drug
Bind collects $70.5M IPO to support Accurin tech

Bind and AstraZeneca, Pfizer, Amgen
Read more on

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.